ClinicalTrials.gg
RecruitingNCT05834764Updated Apr 28, 2023

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

A Phase 2 interventional study of Pyrotinib in HER2-positive Breast Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 101 studies testing pyrotinib in Breast Neoplasms — 49 open to participants now, 57 under way, 13 of them phase 3. pyrotinib · Breast Neoplasms.

Planned enrollment
38th of 101
188 · median 100
Started
2023
with 7 others
Phase 2
63 of 101
30 open now
Primary completion
2026-06
later than 25 of 56 live
Registered
70th of 101
by date
Lead sponsor
5 of 101
The First Affiliated Hospital with Nanjing Medical University

Among the 101 studies testing pyrotinib in Breast Neoplasms, this one is the 38th largest by planned enrollment, is one of 8 that started in 2023, is one of 63 in phase 2, reaches primary completion later than 25 of the 56 other live ones, and was the 70th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

49 of the 101 studies testing pyrotinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 49 open studies →

Where they have run

About pyrotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing pyrotinib in Breast Neoplasms, or all of them as a file.
02

Study summary

ExteNET study explored neratinib prolong anti-HER2 therapy after trastuzumab therapy found that it can improve disease-free survival in patients with lymph nodes positive; In addition, the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve the survival. However, no conclusive conclusions were reached.

However, since the study was carried out early so only trastuzumab treatment was used, it is urgent to carry out research that is more in line with current clinical practice and bring more benefits to patients. To explore whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER2-positive breast cancer after treatment with trastuzumab and pertuzumab or T-DM1.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this study and sign the form;
  2. Female or male patients, aged ≥ 18 years, and ≤75 years;
  3. PS score: 0-1;
  4. Patients with + early or locally advanced breast cancer confirmed by histopathology: HER2-positive is defined by standard of 3+ by immunohistochemical staining (IHC), or 2+ by immunohistochemical staining (IHC) but positive by in situ hybridization (ISH).
  5. Stage II through IIIC HER-2 positive breast cancer with node positive disease after surgery.
  6. Been treated for early breast cancer with standard of care duration of trastuzumab combined with pertuzumab or T-DM1.
  7. Could have been treated neoadjuvantly but have not reached pathologic complete response.

Exclusion criteria

Exclusion Criteria:

  1. disease (Stage IV) or inflammatory breast cancer
  2. Previous or current history of malignant neoplasms, except for curatively treated:Basal and squamous cell carcinoma of the skin,Carcinoma in situ of the cervix.
  3. cardiovascular disease:Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110);
  4. A history of allergy to the drugs in this study;
  5. Unable or unwilling to swallow tablets
  6. History of gastrointestinal disease with diarrhea as the major symptom.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Pyrotinib

    pyrotinib 400mg orally daily for one year

    Drug: Pyrotinib

Interventions

  • Pyrotinib after anti-HER2 therapy(Trastuzumab combined with Pertuzumab or T-DM1)

    Also known as: Pyrotinib maleate

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival (iDFS) at year 2

    Invasive disease-free survival time is defined as the time from date of enrollment until the first disease recurrence or death from any cause.

    Time frame: From enrollment until time of events up to 2 years

Secondary outcomes

  1. Disease-free Survival at year 2 (2y-DFS)

    Disease-free survival time is defined as the time from date of enrollment until the first disease recurrence(including carcinoma in situ)or death from any cause.

    Time frame: From enrollment until time of events up to 2 years

  2. Overall Survival (OS)

    Randomization to death from any cause

    Time frame: Enrollment until death due to any cause, up to 10 years

  3. Invasive Disease-free Survival (iDFS) at year 5

    Invasive disease-free survival time is defined as the time from date of enrollment until the first disease recurrence or death from any cause.

    Time frame: From enrollment until time of events up to 5 years

  4. AEs and SAEs

    Adverse events and Adverse events and serious adverse events according to CACTE 5.0

    Time frame: From the first administration to one months after the last drug administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 37 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
Apr 28, 2023
StartActual
Apr 8, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2028
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05834764
Responsible party
Liu Xiaoan (Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Apr 28, 2023
Start date
Apr 8, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 28, 2023

Study contacts

Xiaoan Liu, Professor
Contact
liuxiaoan@126.com
025-68308162
Xiaoan Liu, Professor
principal investigator · Jiangsu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrotinib

Start the discussion